Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors

Christopher J. Vavricka, Yue Liu, Hiromasa Kiyota, Nongluk Sriwilaijaroen, Jianxun Qi, Kosuke Tanaka, Yan Wu, Qing Li, Yan Li, Jinghua Yan, Yasuo Suzuki, George F. Gao

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Development of novel influenza neuraminidase inhibitors is critical for preparedness against influenza outbreaks. Knowledge of the neuraminidase enzymatic mechanism and transition-state analogue, 2-deoxy-2,3-didehydro-N- acetylneuraminic acid, contributed to the development of the first generation anti-neuraminidase drugs, zanamivir and oseltamivir. However, lack of evidence regarding influenza neuraminidase key catalytic residues has limited strategies for novel neuraminidase inhibitor design. Here, we confirm that influenza neuraminidase conserved Tyr406 is the key catalytic residue that may function as a nucleophile; thus, mechanism-based covalent inhibition of influenza neuraminidase was conceived. Crystallographic studies reveal that 2α,3ax-difluoro-N-acetylneuraminic acid forms a covalent bond with influenza neuraminidase Tyr406 and the compound was found to possess potent anti-influenza activity against both influenza A and B viruses. Our results address many unanswered questions about the influenza neuraminidase catalytic mechanism and demonstrate that covalent inhibition of influenza neuraminidase is a promising and novel strategy for the development of next-generation influenza drugs.

Original languageEnglish
Article number1491
JournalNature Communications
Volume4
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

influenza
Neuraminidase
inhibitors
Human Influenza
Zanamivir
drugs
Influenza B virus
Oseltamivir
Nucleophiles
Covalent bonds
Influenza A virus
acids
N-Acetylneuraminic Acid
nucleophiles
covalent bonds
Viruses
viruses
Pharmaceutical Preparations
Disease Outbreaks

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. / Vavricka, Christopher J.; Liu, Yue; Kiyota, Hiromasa; Sriwilaijaroen, Nongluk; Qi, Jianxun; Tanaka, Kosuke; Wu, Yan; Li, Qing; Li, Yan; Yan, Jinghua; Suzuki, Yasuo; Gao, George F.

In: Nature Communications, Vol. 4, 1491, 2013.

Research output: Contribution to journalArticle

Vavricka, CJ, Liu, Y, Kiyota, H, Sriwilaijaroen, N, Qi, J, Tanaka, K, Wu, Y, Li, Q, Li, Y, Yan, J, Suzuki, Y & Gao, GF 2013, 'Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors', Nature Communications, vol. 4, 1491. https://doi.org/10.1038/ncomms2487
Vavricka, Christopher J. ; Liu, Yue ; Kiyota, Hiromasa ; Sriwilaijaroen, Nongluk ; Qi, Jianxun ; Tanaka, Kosuke ; Wu, Yan ; Li, Qing ; Li, Yan ; Yan, Jinghua ; Suzuki, Yasuo ; Gao, George F. / Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. In: Nature Communications. 2013 ; Vol. 4.
@article{ef57606b078f4fe288f04dc2adc6d4eb,
title = "Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors",
abstract = "Development of novel influenza neuraminidase inhibitors is critical for preparedness against influenza outbreaks. Knowledge of the neuraminidase enzymatic mechanism and transition-state analogue, 2-deoxy-2,3-didehydro-N- acetylneuraminic acid, contributed to the development of the first generation anti-neuraminidase drugs, zanamivir and oseltamivir. However, lack of evidence regarding influenza neuraminidase key catalytic residues has limited strategies for novel neuraminidase inhibitor design. Here, we confirm that influenza neuraminidase conserved Tyr406 is the key catalytic residue that may function as a nucleophile; thus, mechanism-based covalent inhibition of influenza neuraminidase was conceived. Crystallographic studies reveal that 2α,3ax-difluoro-N-acetylneuraminic acid forms a covalent bond with influenza neuraminidase Tyr406 and the compound was found to possess potent anti-influenza activity against both influenza A and B viruses. Our results address many unanswered questions about the influenza neuraminidase catalytic mechanism and demonstrate that covalent inhibition of influenza neuraminidase is a promising and novel strategy for the development of next-generation influenza drugs.",
author = "Vavricka, {Christopher J.} and Yue Liu and Hiromasa Kiyota and Nongluk Sriwilaijaroen and Jianxun Qi and Kosuke Tanaka and Yan Wu and Qing Li and Yan Li and Jinghua Yan and Yasuo Suzuki and Gao, {George F.}",
year = "2013",
doi = "10.1038/ncomms2487",
language = "English",
volume = "4",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors

AU - Vavricka, Christopher J.

AU - Liu, Yue

AU - Kiyota, Hiromasa

AU - Sriwilaijaroen, Nongluk

AU - Qi, Jianxun

AU - Tanaka, Kosuke

AU - Wu, Yan

AU - Li, Qing

AU - Li, Yan

AU - Yan, Jinghua

AU - Suzuki, Yasuo

AU - Gao, George F.

PY - 2013

Y1 - 2013

N2 - Development of novel influenza neuraminidase inhibitors is critical for preparedness against influenza outbreaks. Knowledge of the neuraminidase enzymatic mechanism and transition-state analogue, 2-deoxy-2,3-didehydro-N- acetylneuraminic acid, contributed to the development of the first generation anti-neuraminidase drugs, zanamivir and oseltamivir. However, lack of evidence regarding influenza neuraminidase key catalytic residues has limited strategies for novel neuraminidase inhibitor design. Here, we confirm that influenza neuraminidase conserved Tyr406 is the key catalytic residue that may function as a nucleophile; thus, mechanism-based covalent inhibition of influenza neuraminidase was conceived. Crystallographic studies reveal that 2α,3ax-difluoro-N-acetylneuraminic acid forms a covalent bond with influenza neuraminidase Tyr406 and the compound was found to possess potent anti-influenza activity against both influenza A and B viruses. Our results address many unanswered questions about the influenza neuraminidase catalytic mechanism and demonstrate that covalent inhibition of influenza neuraminidase is a promising and novel strategy for the development of next-generation influenza drugs.

AB - Development of novel influenza neuraminidase inhibitors is critical for preparedness against influenza outbreaks. Knowledge of the neuraminidase enzymatic mechanism and transition-state analogue, 2-deoxy-2,3-didehydro-N- acetylneuraminic acid, contributed to the development of the first generation anti-neuraminidase drugs, zanamivir and oseltamivir. However, lack of evidence regarding influenza neuraminidase key catalytic residues has limited strategies for novel neuraminidase inhibitor design. Here, we confirm that influenza neuraminidase conserved Tyr406 is the key catalytic residue that may function as a nucleophile; thus, mechanism-based covalent inhibition of influenza neuraminidase was conceived. Crystallographic studies reveal that 2α,3ax-difluoro-N-acetylneuraminic acid forms a covalent bond with influenza neuraminidase Tyr406 and the compound was found to possess potent anti-influenza activity against both influenza A and B viruses. Our results address many unanswered questions about the influenza neuraminidase catalytic mechanism and demonstrate that covalent inhibition of influenza neuraminidase is a promising and novel strategy for the development of next-generation influenza drugs.

UR - http://www.scopus.com/inward/record.url?scp=84874604902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874604902&partnerID=8YFLogxK

U2 - 10.1038/ncomms2487

DO - 10.1038/ncomms2487

M3 - Article

C2 - 23422659

AN - SCOPUS:84874604902

VL - 4

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 1491

ER -